FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213047941> ?p ?o ?g. }

• W3213047941 endingPage "709" @default.
• W3213047941 startingPage "701" @default.
• W3213047941 abstract "Tuberculosis (TB) is one of the top ten causes of death worldwide, while Chagas disease (CD) is the parasitic disease that kills the largest number of people in the Americas. TB is the leading cause of death for patients with AIDS; it kills 1.5 million people and causes 10 million new cases every year. The lack of newly developed chemotherapeutic agents and insufficient access to health care services for a diagnosis increase the incidence of multidrug-resistant TB (MDRTB) cases. Although CD was identified in 1909, the chronic stages of the disease still lack adequate treatment.The purpose of this work was to design and synthesize two new series of 2-nitroimidazole 5a-e and imidazooxazoles 6a-e with 1H-1,2,3-triazolil nucleus and evaluate their activities against Tc and Mycobacterium tuberculosis (Mtb).Two series of five compounds were synthesized in a 3 or 4-step route in moderated yields, and their structures were confirmed by NMR spectral data analyses. The in vitro antitrypanosomal evaluation of products was carried out in an intracellular model using L929 cell line infected with trypomastigotes and amastigote forms of Tc of β-galactosidase-transfected Tulahuen strain. Their antimycobacterial activity was evaluated against Mtb strain H37Rv.In general, 2-nitroimidazolic derivatives proved to be more potent in regard to antitrypanocidal and antimycobacterial activity. The non-cytotoxic 2-nitroimidazole derivative 5b was the most promising with a half maximum inhibitory concentration of 3.2 μM against Tc and a minimum inhibitory concentration of 65.3 μM against Mtb.Our study reinforced the importance of 2-nitroimidazole and 1H-1,2,3-triazole nuclei in antimicrobial activity. In addition, derivative 5b proved to be the most promising, presenting important activity against Tc and Mtb and could be used as a starting point for the development of new agents against these diseases." @default.
• W3213047941 created "2021-11-22" @default.
• W3213047941 creator A5000506024 @default.
• W3213047941 creator A5006612928 @default.
• W3213047941 creator A5010467948 @default.
• W3213047941 creator A5017120825 @default.
• W3213047941 creator A5020026115 @default.
• W3213047941 creator A5038116316 @default.
• W3213047941 creator A5043178344 @default.
• W3213047941 creator A5049366282 @default.
• W3213047941 creator A5050132719 @default.
• W3213047941 creator A5061235432 @default.
• W3213047941 creator A5066442059 @default.
• W3213047941 creator A5081931507 @default.
• W3213047941 date "2022-07-01" @default.
• W3213047941 modified "2023-10-16" @default.
• W3213047941 title "Novel 2-Nitroimidazole and Imidazooxazole Derivatives and their Activity against Trypanosoma cruzi and Mycobacterium tuberculosis" @default.
• W3213047941 cites W1541037889 @default.
• W3213047941 cites W1981856785 @default.
• W3213047941 cites W1987879445 @default.
• W3213047941 cites W1990624278 @default.
• W3213047941 cites W2088429109 @default.
• W3213047941 cites W2093843319 @default.
• W3213047941 cites W2123036849 @default.
• W3213047941 cites W2125888372 @default.
• W3213047941 cites W2135732933 @default.
• W3213047941 cites W2160787060 @default.
• W3213047941 cites W2283970232 @default.
• W3213047941 cites W2737548993 @default.
• W3213047941 cites W2779646623 @default.
• W3213047941 cites W2789752004 @default.
• W3213047941 cites W2791727539 @default.
• W3213047941 cites W2808947823 @default.
• W3213047941 cites W2967724273 @default.
• W3213047941 cites W2989215041 @default.
• W3213047941 doi "https://doi.org/10.2174/1573406418666211116144952" @default.
• W3213047941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34784878" @default.
• W3213047941 hasPublicationYear "2022" @default.
• W3213047941 type Work @default.
• W3213047941 sameAs 3213047941 @default.
• W3213047941 citedByCount "3" @default.
• W3213047941 countsByYear W32130479412013 @default.
• W3213047941 countsByYear W32130479412023 @default.
• W3213047941 crossrefType "journal-article" @default.
• W3213047941 hasAuthorship W3213047941A5000506024 @default.
• W3213047941 hasAuthorship W3213047941A5006612928 @default.
• W3213047941 hasAuthorship W3213047941A5010467948 @default.
• W3213047941 hasAuthorship W3213047941A5017120825 @default.
• W3213047941 hasAuthorship W3213047941A5020026115 @default.
• W3213047941 hasAuthorship W3213047941A5038116316 @default.
• W3213047941 hasAuthorship W3213047941A5043178344 @default.
• W3213047941 hasAuthorship W3213047941A5049366282 @default.
• W3213047941 hasAuthorship W3213047941A5050132719 @default.
• W3213047941 hasAuthorship W3213047941A5061235432 @default.
• W3213047941 hasAuthorship W3213047941A5066442059 @default.
• W3213047941 hasAuthorship W3213047941A5081931507 @default.
• W3213047941 hasConcept C136764020 @default.
• W3213047941 hasConcept C142724271 @default.
• W3213047941 hasConcept C2777625466 @default.
• W3213047941 hasConcept C2777975735 @default.
• W3213047941 hasConcept C2779685592 @default.
• W3213047941 hasConcept C2780374374 @default.
• W3213047941 hasConcept C2781047020 @default.
• W3213047941 hasConcept C2781069245 @default.
• W3213047941 hasConcept C2781092759 @default.
• W3213047941 hasConcept C41008148 @default.
• W3213047941 hasConcept C71924100 @default.
• W3213047941 hasConcept C71928629 @default.
• W3213047941 hasConcept C86803240 @default.
• W3213047941 hasConcept C89423630 @default.
• W3213047941 hasConcept C98274493 @default.
• W3213047941 hasConcept C98319499 @default.
• W3213047941 hasConceptScore W3213047941C136764020 @default.
• W3213047941 hasConceptScore W3213047941C142724271 @default.
• W3213047941 hasConceptScore W3213047941C2777625466 @default.
• W3213047941 hasConceptScore W3213047941C2777975735 @default.
• W3213047941 hasConceptScore W3213047941C2779685592 @default.
• W3213047941 hasConceptScore W3213047941C2780374374 @default.
• W3213047941 hasConceptScore W3213047941C2781047020 @default.
• W3213047941 hasConceptScore W3213047941C2781069245 @default.
• W3213047941 hasConceptScore W3213047941C2781092759 @default.
• W3213047941 hasConceptScore W3213047941C41008148 @default.
• W3213047941 hasConceptScore W3213047941C71924100 @default.
• W3213047941 hasConceptScore W3213047941C71928629 @default.
• W3213047941 hasConceptScore W3213047941C86803240 @default.
• W3213047941 hasConceptScore W3213047941C89423630 @default.
• W3213047941 hasConceptScore W3213047941C98274493 @default.
• W3213047941 hasConceptScore W3213047941C98319499 @default.
• W3213047941 hasFunder F4320322025 @default.
• W3213047941 hasFunder F4320322749 @default.
• W3213047941 hasIssue "6" @default.
• W3213047941 hasLocation W32130479411 @default.
• W3213047941 hasLocation W32130479412 @default.
• W3213047941 hasOpenAccess W3213047941 @default.
• W3213047941 hasPrimaryLocation W32130479411 @default.
• W3213047941 hasRelatedWork W1966448483 @default.
• W3213047941 hasRelatedWork W1994677231 @default.
• W3213047941 hasRelatedWork W1997276814 @default.

• next